SCHEMBL6719347

SCHEMBL6719347

CCCCCCCCCCCC([C]=O)c1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAAA Q02083 2/20 0.43
HTR2A P28223 1/20 0.41
ASAH1 Q13510 2/20 0.41
KCNH2 Q12809 1/20 0.41
PRSS1 P07477 1/20 0.41
PRSS2 P07478 1/20 0.41
PRSS3 P35030 1/20 0.41
CSNK1E P49674 1/20 0.41
ALDH1A1 P00352 2/20 0.40
ACER2 Q5QJU3 1/20 0.40
MMP2 P08253 2/20 0.40
MMP9 P14780 2/20 0.40
MMP12 P39900 1/20 0.40
OPRM1 P35372 1/20 0.40
OPRD1 P41143 1/20 0.40
OPRK1 P41145 1/20 0.40
OPRL1 P41146 1/20 0.40
POLB P06746 1/20 0.40
CNR2 P34972 1/20 0.40
SIGMAR1 Q99720 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7454537 1.00 NAAA (0.43) NAAAHTR2AASAH1KCNH2PRSS1
SCHEMBL11834538 1.00 NAAA (0.43) NAAAHTR2AASAH1KCNH2PRSS1
SCHEMBL6723008 1.00 NAAA (0.43) NAAAHTR2AASAH1KCNH2PRSS1
SCHEMBL7455004 1.00 NAAA (0.43) NAAAHTR2AASAH1KCNH2PRSS1
SCHEMBL7452348 1.00 NAAA (0.43) NAAAHTR2AASAH1KCNH2PRSS1
SCHEMBL7454063 1.00 NAAA (0.43) NAAAHTR2AASAH1KCNH2PRSS1
SCHEMBL7458136 1.00 NAAA (0.43) NAAAHTR2AASAH1KCNH2PRSS1
SCHEMBL6723122 0.98 NAAA (0.41) NAAAHTR2AASAH1KCNH2PRSS1
SCHEMBL143657 0.93 POLB (0.45) NAAAHTR2AALDH1A1OPRM1OPRD1
SCHEMBL28799952 0.85 AOC3 (0.42) HTR2APOLBSIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040127433-A1 excellent antibacterial activity especially against a typical acid-fast mycobacteria including multiple drug-resistant bacteria HOKURIKU SEIYAKU CO., LTD. (JP) 2004-07-01 US disclosed
EP-1323726-A1 ERYTHROMYCIN DERIVATIVES AND MEDICINES CONTAINING THE SAME HOKURIKU SEIYAKU CO., LTD. (JP) 2003-07-02 EP disclosed
EP-1167375-A1 ERYTHROMYCIN DERIVATIVES HOKURIKU SEIYAKU CO., LTD. (JP) 2002-01-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040127433-A1 excellent antibacterial activity especially against a typical acid-fast mycobacteria including multiple drug-resistant bacteria MAPRE1, MAPRE2, MRPS27 NAAA 1333/4885HTR2A 4356/4885ASAH1 2447/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.